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Shimiao Zhu1†, Yang Tang1†, Kai Li2†, Zhiqun Shang1, Ning Jiang1, Xuewu Nian1, Libin Sun1 and Yuanjie Niu1*Abstract
Background: To explore the necessity of maintenance, efficacy of low-dose and superiority of various combination
therapies of Bacillus Calmette-Guérin (BCG) in treatment of superficial bladder cancer (BCa).
Methods: Comprehensive searches of electronic databases (PubMed, Embase, and the Cochrane Library) were
performed, then a systematic review and cumulative meta-analysis of 21 randomized controlled trials (RCTs) and 9
retrospective comparative studies were carried out according to predefined inclusion criteria.
Results: Significantly better recurrence-free survivals (RFS) were observed respectively in patients who received BCG
maintenance, standard-dose and BCG plus epirubicin therapy comparing to those received induction, low-dose and
BCG alone. BCG maintenance therapy was also associated with significantly better progression-free survival (PFS),
but there were more incidences of adverse events. Pooled results showed no remarkable advantage of BCG
combined with Mitomycin C or with interferon α-2b in improving oncologic outcomes. Sensitivity-analyses stratified
by study-design and tumor stage led to very similar overall results and often to a decrease of the between-study
heterogeneity. Our data confirmed that non-RCT only affected strength rather than direction of the overall results.
Conclusions: All patients with superficial BCa should be encouraged to accept BCG maintenance therapy with
standard-dose if well tolerated. Patients can benefit from BCG combined with epirubicin but not from BCG
combined with Mitomycin C or interferon α-2b.
Keywords: Bacillus Calmette-Guérin, Non-muscle-invasive bladder cancer, Maintenance therapy, Low-dose,
Combination therapy, PrognosisBackground
More than 30 years ago, intravesical Bacillus Calmette-
Guérin (BCG) was first proposed by Morales [1]. Since
then, BCG therapy has been demonstrated to be the
most effective treatment in the prevention of the recur-
rence and progression of superficial bladder cancer
(BCa), especially for high-risk non-muscle-invasive blad-
der cancer (NMIBC) [2]. Despite its well-recognized effi-
cacy, many questions remain suspended and among
them, the following ones should be noted: 1) the neces-
sity of maintenance BCG therapy; 2) the efficacy of low-* Correspondence: yuanjieniu68@hotmail.com
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reproduction in any medium, provided the ordose BCG; and 3) the superiority of combination therapy
of BCG.
Previous studies showed that only maintenance BCG
could benefit patients in reducing tumor progression
[3,4]. However, the results were from studies comparing
maintenance BCG with Mitomycin C (MMC) other than
BCG induction, and high-level direct evidence suppor-
ting maintenance therapy was still absent. The mainten-
ance BCG has been compromised because of serious
side-effects (e.g., BCG sepsis and BCG-induced cystitis).
Then, low-dose BCG [5-7], recognized to be accompa-
nying with reduced side effects, was introduced. Higher
recurrence and progression rates were observed in low-
dose group comparing with standard-dose group [5-7],
nevertheless, the wide confidential intervals (CI) of indi-
vidual studies made us failed to detect significant. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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us to perform meta-analyses to systematically evaluate
the necessity of maintenance BCG and the efficacy of
low-dose BCG therapy.
Additionally to optimize the BCG therapy schedules,
efficacy of BCG combination therapies (e.g. BCG plus
MMC, BCG plus epirubicin and BCG plus interferon
α-2b (IFN-α2b)) were also evaluated in this meta-
analysis. Many studies had been addressed to improve
BCG efficacy by combining with other remedies [8],
however, no consistent conclusion was obtained. Thus,
the systematic syntheses were addressed to explore the
optimal schedule and dose of BCG prescription for
NMIBC.Methods
Search strategy and study selection
This meta-analysis was conducted according to the Pre-
ferred Reporting Items for Systematic Reviews and Meta-
Analyses (PRISMA) [9]. A systematic search of Medline,
Embase, and the Cochrane Library was performed using
all possible combinations of the following keywords: 1)
‘Low-Dose’ or ‘Low doses’ or ‘maintenance instillation’ or
‘maintenance’ or ‘Mitomycin C’ or ‘MMC’ or ‘Epirubicin’
or ‘interferon’ or ‘IFN’ or ‘combination therapy’ and ‘BCG’
or ‘Bacillus Calmette-Guérin’ and ‘bladder cancer’ or
‘Transitional cell carcinoma of bladder’ or ‘urothelial car-
cinoma of bladder’; 2) and ‘BCG’ or ‘Bacillus Calmette-Gu
érin’ and ‘bladder cancer’ or ‘Transitional cell carcinoma
of bladder’ or ‘urothelial carcinoma of bladder’. To per-
form an extensive search, no language, publication year, or
other limits were used. The last quest was updated on
March 7, 2013. Reference lists of relevant reviews were
hand-searched to identify additional studies.
Eligible studies had to meet the following inclusion
criteria: (1) The diagnosis of BCa had to be confirmed
pathologically; (2) All patients should be confirmed as
NMIBC; (3) Included studies had to provide comparative
data; and (4) Only the most recent trials with the
greatest number of patients was chosen when over-
lapped subjects were selected in more than one study.Data extraction and quality assessment
Informations were carefully extracted from all eligible
publications independently by two authors, and all dis-
agreements were resolved by the third reviewer (Niu)
until consensus was achieved on all items. The following
data were considered in eligible studies: author name,
year and country of the trials, numbers of case and con-
trol subjects, age, duration of follow-up, Treatment
schedules and doses of medicines, Hazard Ratios (HRs)
or Risk Ratios (RRs) and corresponding 95% CIs of each
comparisons.The methodological quality of RCT was assessed by
the Jadad scale [10], considering that a high quality RCT
should get more than 3 points. The retrospective studies
were assessed by the Newcastle-Ottawa scale [11].
Observational studies achieving six or more stars were
considered to be of high quality. Assessments were
addressed independently by two authors and the dis-
agreements between authors are resolved by discussion.
Additionally, all included studies were also evaluated
according to the level of evidence (LOE) stated by Phil-
lips et al. [12].
Statistical analysis
The recurrence-free survival (RFS) and Progression-free
survival (PFS) were evaluated to assess the effects of
various treatment schedules and doses. The HRs or Risk
Differences (RDs) were used to compare all dichotomous
variables. HRs were estimated by different methods de-
pending on the data provided in the publication. The
simplest method was to collect reported HRs and their
95% CIs in texts. If those data were not available, we
looked for the total number of events, the number of pa-
tients at risk in each group and the logrank statistic or
its P value allowing calculation of an approximation of
the HR estimate. If data were only available in the form
of survival curve (SC), we extracted from the survival
rates at some specified times so as to estimate the HR
value and its variance, assuming that the rate of patients
censored was constant during the study follow-up [13].
If the data mentioned above were not available, risk ratio
should be considered as the last option. To avoid poten-
tial publication bias caused by cherry-picking, compara-
tive studies were identified no matter of study design.
Then, sensitivity analysis stratified by study-design was
conducted to decrease potentially introduced bias by
observational studies. In addition, sensitivity analysis
stratified by tumor stage was addressed to narrow the
population that was suitable for indicated treatment.
Statistical heterogeneity between trials included in the
meta-analysis was assessed using Cochrane’s Q statistic
[14] . And the inconsistency was quantified by I2 statistic
(100%×[(Q-df )/Q]), higher value denoting greater degree
of heterogeneity [15]. Fixed-effects model was used
when heterogeneity was not observed; otherwise, random-
effects model was used. Fixed-effects model, using the
Mantel–Haenszel method, assumed that studies were
sampled from populations with the same effect size;
whereas the random-effects model, using the Der-
Simonian and Laird method, considered that studies were
taken from populations with different effect sizes.
Publication bias was evaluated using Begg adjusted rank
correlation test and Egger linear regression test. All statis-
tical analyses were conducted using STATA (version 11.0;
College Station, Texas) and Review Manage (version 5.1;
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of less than .05 was considered statistically significant.
Results
Literature search and characteristics of the included
studies
After removing 692 duplicates, we screened 755 poten-
tially relevant articles. The final number of papers in-
cluded in the meta-analysis was 30, list of studies
excluded and reasons were shown in Figure 1. Of these,
nine were identified to explore the necessity of BCG
maintenance [16-24], seven investigate the efficacy of
low-dose BCG [5-7,25-28], and the remainders address
the effects of BCG combination therapy [29-42]. There
were 21 randomized-controlled trails (RCTs), eight
retrospective studies and one case-series study. Search
of the references listed in reviews did not yield any fur-
ther available studies. Agreement between the two re-
viewers was 96% for study selection and 96% for quality
assessment of trials.
The characteristics of included studies were shown in
Tables 1, 2 and 3. Among the RCTs, there were 5 high
quality studies (level of evidence: 2b) [6,22,24,33,38].
The severe side-effects that can be easily recognized by
both patients and researchers made most of studies
failed to use double-blind method, which should be re-
sponsible for the low-quality of included RCTs. Only 11447 of records identified
692 duplicates removed
755 of records screened
590 records removed based on abstract
165 full-text articles assessed for eligibility
135 articles excluded
61 not related topic
29 no comparative data
26 experiment data
17 no original data
2 overlapped data
30 studies included in meta-analysis
Figure 1 Flowchart of selecting process for meta-analysis.retrospective studies which didn’t adopt appropriate
protocol for treatment assignment and used historical
series as controls were recognized as low quality case-
series study (level of evidence: 4) [42]. The results of
quality assessment were listed in Additional file 1: Table S2
and Table S3.
Meta-analysis results
BCG maintenance vs. induction alone
In this meta-analysis of comparative studies, nine studies
were identified to investigate the necessity of BCG main-
tenance therapy [16-24]. Pooled results of data that
assessed tumor recurrence rate showed that BCG mainten-
ance therapy could significantly improve RFS (HR=0.516;
95% CI 0.425-0.627; P<0.0001) (Figure 2A), comparing
with BCG induction. Cancer progression rates were inves-
tigated in 7 studies, and a notable advantage of BCG main-
tenance in improving PFS was also observed (HR=0.740;
95% CI 0.572-0.957; P=0.022) (Figure 2B). Five studies
were available to explore the RFS and PFS in high-risk
NMIBC patients underwent BCG maintenance or induc-
tion therapy [16,18,19,21,22], significant differences were
presented between the two treatment schedules (RFS:
HR=0.515, 95% CI 0.411-0.646, P<0.0001; PFS: HR=0.722,
95% CI 0.548-0.951, P=0.020) (Table 4). No heterogeneity
among included studies was significant for the above all
analyses (Table 4).
Low-dose vs. standard-dose BCG
In term of RFS, six studies [5-7,25-28] including 998 cases
and 1018 controls were identified to comparing low dose
BCG to standard doses, cumulated result showed a
remarkable difference opposing to low-dose BCG
(HR=1.162; 95% CI 1.051-1.285; P=0.003) (Figure 3A).
Pooling data of 5 studies [5-7,25,26,28] including 1,942
patients that reported tumor progression rate showed the
PFS was lower in low-dose BCG than in control group,
but this difference was not statistically significant
(HR=1.151; 95% CI 0.853-1.554; P=0.356) (Figure 3B). Sig-
nificant heterogeneity was detected in neither analysis
above (Table 4).
BCG plus mitomycin C vs. BCG alone
Six studies involving 979 patients with superficial BCa
were identified to investigate the difference between
therapy schedules of BCG alone and BCG plus MMC
[29-34], synthesized data showed no significantly better
RFS in patients accepted combined therapy (HR=0.726;
95% CI 0.490-1.075; P=0.110) (Figure 4A). High-risk
NMIBC was evaluated in 3 of above 5 studies [30,33,34],
also no significant result was observed (HR=0.852; 95%
CI 0.449-1.617; P=0.624). Tumor progression rate was
available in 3 studies, in these studies, only high-risk
NMIBC patients were included [30,33,34]. Pooled analysis
Table 1 Characteristics of studies investigating the effects of maintenance of BCG






Disease category Follow-up, mo
Case/Control*
Strain Treatment dose (mg)
Maintenance/Induction
Badalament 1987 [23] RCT, 1b 47/46 62.0/63.5 Superficial BCa 22(3–44) Pasteur 120/120
Koga 2010 [18] RCT, 1b 24/27 NA High-risk NMIBC 26.5/28.7 Tokyo 80/80
Hinotsu 2011 [16] RCT, 1b 41/42 NA Recurrent or multiple NMIBC 24 Connaught 80/40
Lamm 2000 [22] RCT, 1b 192/192 66.8/67.0 Recurrent Ta, T1 and CIS 119.1/120.3 Connaught 80/40
Palou 2001 [21] RCT, 1b 65/61 65.0/63.0 CIS and/or high grade BCa 77.8(7–120) Connaught 81/81
Hudson 1987 [24] RCT, 1b 21/21 60.0/62.0 Superficial BCa 16.1±1.4 Pasteur 120/120
Andius 2004 [20] R, 2b 52/80 74(31–96) NMIBC without CIS 44(4–155) Danish/OncoTice NA
Okamura 2011 [17] R, 2b 48/27 64.0/68.0 NMIBC without CIS 102/66 Tokyo 172 80/80
Decobert 2008 [19] R, 2b 31/40 64.3/69.5 High-risk NMIBC 31 Pacis 120/120
LOE Level of evidence, RCT Randomized-controlled trial, R Retrospective, NMIBC Non-muscle-invasive bladder cancer, BCa Bladder cancer, CIS Carcinoma in suit, NA Not available, Case/Control,
BCG maintenance/Induction.

















Table 2 Characteristics of studies investigating the effects of low-dose BCG






Disease category Follow-up, mo
Case/Control*




Ojea 2007 [25] RCT, 1b 139/142 64.9/65.1 Intermediate-Risk NMIBC 61.2/57.3 Connaught 13.5/27 Yes/Yes
Yalcinkaya 1998 [7] RCT, 1b 25/25 56.3/55.3 Superficial BCa 26.8/31.6 Connaught 54/81 No/No
Kumar 2002 [6] RCT, 2b 13/13 55.9/56.7 NMIBC without CIS 24(12–30) Danish 1331 40/120 No/No
Oddens 2013 [28] RCT, 1b 678/677 68.0/67.0 Intermediate and high risk NMIBC 85.2 OncoTice 27/81 Yes/Yes
Takashi 1995 [27] R, 2b 37/37 68.1/61.4 Superficial BCa 32 Tokyo 172 40/80 No/No
Yoneyama 2008 [5] R, 2b 65/85 68.3/65.5 NMIBC without CIS 42.2/90.7 Tokyo 172 40/80 No/No
Irie 2003 [26] R, 2b 41/39 61.6/62.2 Superficial BCa 27.5/20.0 Tokyo 172 40/80 No/No
LOE Level of evidence, RCT Randomized-controlled trial, R Retrospective, NMIBC Non-muscle-invasive bladder cancer, BCa Bladder cancer, Case/Control, Low-dose/Standard-dose BCG.
* Mean or median.

















Table 3 Characteristics of studies investigating Combination BCG therapies
First author, yr Design,
LOE
No. of Age* Disease category Follow-up, mo Strain Treatment schedules
Case/Control Case/Control Case/Control* Case Control
BCG plus mitomycin C vs. BCG alone (Case vs. Control)
Kaasinen 2003 [34] RCT, 1b 159/145 71.0/69.9 CIS 56.3(1.9-97.3) Connaught 6 weekly BCG plus alternating BCG
and MMC monthly
6 weekly BCG plus
monthly BCG
Stasi 2006 [33] RCT, 1b 107/105 66.0/67.0 High-risk NMIBC 91/84 Connaught 2 weekly BCG and 1 week MMC as
one cycle for three cycles**
6 weekly BCG**
Oosterlinck 2011 [30] RCT, 1b 48/48 68.0/70.0 CIS 56.4 Tice 6 weekly MMC plus 6 weekly BCG** 6 weekly BCG plus 3
weekly rest and BCG**
Gulpinar 2012 [29] RCT, 1b 25/26 58.2/58.0 Intermediate-Risk NMIBC 41.3/40.9 Tice Perioperative MMC plus 6 weekly
BCG
6 weekly BCG
El Mohsen 2010 [32] RCT 1b 29/27 47.5/48.1 Superficial BCa 30 NA Perioperative MMC plus 4 weekly
MMC plus monthly BCG for 1 year
6 weekly BCG plus
monthly BCG for 1 year
Badalato 2011 [31] R, 2b 48/212 69.6/69.6 Superficial BCa 33.0/43.6 Connaught Perioperative MMC plus 6 weekly
BCG**
6 weekly BCG **
BCG plus mitomycin C vs. mitomycin C alone (Case vs. Control)
Rintala 1996 [37] RCT, 1b 95/93 68/69 Rapidly recurring NMIBC 34(1–76) Pasteur Alternating courses of MMC and BCG
monthly during year 1 and every 3
months during year 2
MMC monthly during
year 1 and every 3
months during year 2
Jarvinen 2012 [35] RCT, 1b 28/40 66/68 CIS 408 Pasteur Ditto Ditto
Witjes 1998 [36] RCT, 1b 90/92 NA Intermediate-Risk NMIBC 32(2–65) Tice 4 weekly MMC followed by 6 weekly
BCG
10 weekly MMC
BCG plus Epirubicin vs. BCG alone (Case vs. Control)
Cai 2008 [38] RCT, 1b 80/81 73.9/69.8 High-risk NMIBC 15.3/14.8 OncoTice Perioperative epirubicin plus delayed
BCG
6 weekly BCG and every
3 months for
maintenance
Bilen 2000 [40] RCT, 1b 20/21 57/53 High-risk NMIBC 18(9–24) Connaught Sequential instillation of BCG and
epirubicin for 8 weeks
6 weekly BCG
Tozawa 2001 [39] R, 2b 24/50 67.9/65.6 Superficial BCa without CIS 6-36 Tokyo Epirubicin and BCG were instilled by
turns once a week for 12 weeks
6 weekly plus six
monthly BCG
BCG plus Interferon α-2b vs. BCG alone (Case vs. Control)
Nepple 2010 [41] RCT, 1b 346/324 68.4 Superficial BCa NA Tice 6 weekly BCG plus IFN** 6 weekly BCG **
Bazarbashi 2000 [42] C-S, 4 37/18 59/58 Superficial BCa 26.2/23.8 Connaught Weekly sequential BCG and IFN for 8
weeks
6 weekly BCG
LOE Level of evidence, RCT Randomized-controlled trial, R Retrospective, C-S Case-series, NMIBC Non-muscle-invasive bladder cancer, BCa Bladder cancer, CIS Carcinoma in suit, NA Not available.
* Mean or median.

















Figure 2 Forest plots of pooled results (A, recurrence-free survival; B, progression-free survival) for the maintenance group and
non-maintenance group.
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plus Mitomycin C and BCG alone (HR=0.602; 95% CI
0.181-1.999; P=0.407) (Figure 4B). There were significant
heterogeneities in all above 3 analyses, so random-effect
models were selected (Table 4).
BCG plus mitomycin C vs. mitomycin C alone
Pooled data of 3 RCTs [35-37] didn’t revealed BCG plus
MMC significantly improved the RFS or PFS of patients
with superficial BCa comparing with MMC alone (RFS:
HR=0.854, 95% CI 0.663-1.099, P=0.220; PFS: HR=0.927,
95% CI 0.482-1.784, P=0.822) (Figure 5A and B). High-
risk NMIBC were investigated in 2 studies [35,37],integrated data also failed to detect remarkable advan-
tage of combined therapy in reducing recurrence and
progression rates comparing to MMC alone (RFS:
HR=0.797, 95% CI 0.477-1.330, P=0.385; PFS: HR=0.829,
95% CI 0.387-1.773, P=0.628). There is no evidence of
between-study heterogeneity in these analyses men-
tioned above (Table 4).
BCG plus epirubicin vs. BCG alone
Evidence from 3 studies [38-40] showed that combination
of BCG and epirubicin could significantly prevent or delay
the recurrence of superficial BCa (HR=0.618; 95% CI 0.384-
0.993; P=0.047) (Figure 6A). The combination therapy had
Table 4 Pooled results of recurrence-free survival, progression-free survival and publication bias of comparing various
BCG treatment schedules and doses
Measurement n* Case or
case
control
Heterogeneity Pooled rate / HR Begg’s
test (P)
Egger’s
test (P)P I2 (%) (95% CI)
Recurrence-free survival
Superficial bladder cancer
Maintenance vs. Induction 9 521/536 0.150 12.0 0.516 (0.425-0.627) 0.602 0.353
Low-dose vs. Standard-dose 7 998/1018 0.831 0.00 1.162 (1.051-1.285) 1.000 0.126
BCG plus MMC vs. BCG 6 416/563 <0.001 79.1 0.726 (0.490-1.075) 0.452 0.334
BCG plus MMC vs. MMC 3 213/225 0.297 17.7 0.854 (0.663-1.099) 0.296 0.132
BCG plus Epirubicin vs. BCG 3 124/152 0.652 0.00 0.618 (0.384-0.993) 1.000 0.538
BCG plus IFN-α2b vs. BCG 2 383/342 0.621 0.00 1.075 (0.859-1.345) 1.000 NA
High-risk NMIBC
Maintenance vs. Induction 5 353/362 0.272 22.4 0.515 (0.411-0.646) 0.086 0.032
BCG plus MMC vs. BCG 3 314/298 <0.001 89.8 0.852 (0.449-1.617) 1.000 0.689
BCG plus MMC vs. MMC 2 123/133 0.119 58.7 0.797 (0.477-1.330) 1.000 NA
BCG plus Epirubicin vs. BCG 2 100/102 0.556 0.00 0.544 (0.302-0.980) 1.000 NA
Progression-free survival
Superficial bladder cancer
Maintenance vs. Induction 7 452/488 0.380 6.20 0.740 (0.572-0.957) 0.764 0.399
Low-dose vs. Standard-dose 6 961/981 0.829 0.00 1.151 (0.853-1.554) 0.452 0.112
BCG plus MMC vs. BCG 3 314/298 0.001 85.3 0.602 (0.181-1.999) 1.000 0.420
BCG plus MMC vs. MMC 3 213/225 0.827 0.00 0.927 (0.482-1.784) 1.000 0.493
BCG plus Epirubicin vs. BCG 2 100/102 0.980 0.00 0.513 (0.132-1.987) 1.000 NA
High-risk NMIBC
Maintenance vs. Induction 5 353/362 0.581 0.00 0.722 (0.548-0.951) 0.806 0.311
BCG plus MMC vs. BCG 3 314/298 0.001 85.3 0.602 (0.181-1.999) 1.000 0.420
BCG plus MMC vs. MMC 2 123/133 0.813 0.00 0.829 (0.387-1.773) 1.000 NA
BCG plus Epirubicin vs. BCG 2 100/102 0.980 0.00 0.513 (0.132-1.987) 1.000 NA
NA not applicable. Significant datas are emphasized in bold.
* Number of included studies.
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from recurrence (HR=0.544; 95% CI 0.302-0.980; P=0.043).
Progression rate was reported in 2 studies including 202
high-risk NMIBC patients [38,40], better outcome was ob-
served in patients received combined therapy of BCG plus
epirubicin, but this difference was not statistically signifi-
cant (HR=0.513; 95% CI 0.132-1.987; P=0.334) (Figure 6B).
The homogeneity among included studies was recognized
by heterogeneity test (Table 4).BCG plus interferon α-2b vs. BCG alone
Only RFS was discussed for this comparison, no sig-
nificant difference was found between the two
groups (HR=1.075; 95% CI 0.859-1.345; P=0.527)
(Figure 7), and no evidence of heterogeneity was
presented (Table 4).Complications of treatment
One of the most important indicators of complications
was the percentage of patients who are unable to
complete the treatment course because of side effects.
Unfortunately, only therapy schedule of BCG plus MMC
could be assessed by cessation rate due to side effects.
As shown in Additional file 1: Figure S1, less cessation
occurred in group of BCG plus MMC comparing to
BCG or MMC alone, but no significant difference was
detected (HR=0.553, 95% CI 0.170-1.797, P=0.325;
HR=0.696, 95% CI 0.334-1.454, P=0.335; respectively).
Then the side effects accompanied with therapy were
evaluated to oppose treatment efficacy. Numbers of limi-
tation emerged hindering us from evaluating side effects
caused by various therapy schedules and doses: 1) de-
scriptors reported in individual articles were of great
difference; 2) variety of terms were used to report
Figure 3 Forest plots of pooled results (A, recurrence-free survival; B, progression-free survival) for the low-dose group and
standard-dose group.
Zhu et al. BMC Cancer 2013, 13:332 Page 9 of 15
http://www.biomedcentral.com/1471-2407/13/332complications; 3) only simple descriptions of complica-
tions were present in the most of included studies. The
AUA guidelines panel for NMIBC combined complica-
tions into a set of categories [43]: bladder contracture,
epididymitis/prostatitis/urethral infections, hematuria,
lower urinary tract symptoms (LUTS) (including fre-
quency, urgency, dysuria, etc.), fever/chills/flu symp-
toms, and systemic infection. According to the guideline
panel, side-effects rates were present in a manner of
‘maximal overlap’, since it’s unlikely that each patient
had only one symptom. For example, a chilled man usu-
ally gets into fever. Maximal overlap indicates thatdifferent symptoms within the same category occurred
simultaneously in the same patients [43].
Additional file 1: Table S1 listed common complica-
tions related to various treatments. The most common
local and systemic side effects are LUTS and flu-like
symptoms, respectively. Pooled risk differences of side
effects that caused by different therapy schedules were
showed in Additional file 1: Figure S2. The occurrence
of local (e.g. hematuria and LUTS) and systemic (e.g.
flu-like symptoms) side effects were both significantly
elevated by maintenance therapy. Low-dose BCG only
reduced the incidence of LUTS with a cautious
Figure 4 Forest plots of pooled results (A, recurrence-free survival; B, progression-free survival) for the BCG plus Mitomycin C group
and BCG alone group.
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in other comparisons.
Sensitivity analysis and publication bias
For sensitivity analysis, we only included RCT. Subgroup
data showed that BCG maintenance was no longer sig-
nificantly prevent patients from getting the chance of
progression (HR=0.781; 95% CI 0.598-1.019; P=0.068;
Figure 2B). However, the obvious trend favoring BCG
maintenance could be found still. And there was no sig-
nificant difference between the results obtained from
studies with the two distinct designs (P=0.12). No other
remarkable change was present in subgroup analyses
stratified by study design. For difference between results
obtained from trials and those with other study designs,
the significance was only noted in Figure 1A (P=0.03)
Inclusion of the non-randomized studies might inap-propriately inflate the power of the analyses, thus the
findings on RFS in this analysis should be interpreted
with caution. Data from subgroup-analyses confirmed
that non-RCT only affected strength rather than direc-
tion of the overall results. Another sensitivity analysis
stratified by pathologic tumor stage was also conducted,
as shown in Table 4, no variation was detected. The
Begg’s and Egger’s tests (Table 4) revealed that signifi-
cant publication bias existed in only 1 (BCG mainten-
ance vs. induction for RFS in high-risk NMIBC group)
of all comparisons performed in the present analysis.
Discussion
In this systematic review, we included 21 RCTs and 9
retrospective studies to evaluate the optimal schedule
and dose of BCG for preventing recurrence and progres-
sion of superficial BCa. Pooled data revealed that BCG
Figure 5 Forest plots of pooled results (A, recurrence-free survival; B, progression-free survival) for the BCG plus Mitomycin C group
and Mitomycin C alone group.
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patients with superficial BCa, especially for patients with
high-risk NMIBC. Our results were similar to the indir-
ect evidence proved by Bohle et. al [3] and Sylvester et.
al [4], which showed that maintenance therapy was asso-
ciated with better outcomes, but sole induction course
didn’t seem to have superiority comparing with MMC.
Accompanied with better clinical outcomes, incidence of
adverse events was raised when patients receiving main-
tenance therapy. The potential benefits of BCG mainten-
ance seemed to outweigh the risk of complications, even
it was serious, and especially for patients with tumors
that carried substantial risk of progression and might ul-
timate death from bladder cancer. In a high-quality co-
hort study, Decobert et al. [19] suggested that patients
should be encouraged to tolerate at least 3 cycles of
maintenance and to continue further instillations if well
tolerated. However, serious side-effects caused by long-
term BCG may be unworthy for those with low-risklesions. Andius and Holmang showed that multiple in-
stillation cycles may not be necessary for pTa and lower-
grade tumors [20]. Unfortunately, there is no sufficient
data to state if low-risk NMIBC could benefit from
maintenance therapy. AUA guideline suggested that
these risks and benefits should be discussed with the pa-
tients [43].
This meta-analysis shows that low-dose BCG may be
defective in preventing tumor recurrence, which opposes
to previous studies that clarified no significantly different
RFS existed between low- and standard-doses BCG for
patients with superficial BCa, even for those with high-
risk NMIBC (e.g. T1G3) [5,6,26]. In an effort to reduce
the potential of complications caused by BCG (e.g.
LUTS), pooled results have demonstrated sufficient effi-
cacy using lower dose of BCG. Low-dose BCG can be
chosen by patients with low-risk BCa, and then adverse
effects can be minimized. Nevertheless, there is no evi-
dence support the hypothesis.
Figure 7 Forest plots of pooled results of recurrence-free survival for the BCG plus Interferon α-2b group and BCG alone group.
Figure 6 Forest plots of pooled results (A, recurrence-free survival; B, progression-free survival) for the BCG plus Epirubicin group and
BCG alone group.
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http://www.biomedcentral.com/1471-2407/13/332Evidence in a cautious manner showed that sequential
intravesical epirubicin could improve BCG efficacy re-
garding RFS in patients with superficial BCa (e.g. high-
risk NMIBC). It was logical to deduce that treatment
with sequential chemoimmunotherapy with two different
antitumor mechanisms might be more active than
monotherapy alone. However, pooled results of BCG
combined with MMC diverged from the hypothesis be-
cause we did not find significant difference in terms of
RFS and PFS between patients who received intravesical
MMC plus sequential BCG and those who received only
BCG instillations. Significant heterogeneities were ob-
served in this analysis and corresponding subgroup-
analysis. Slight difference of treatment schemes existed
in the therapy schedules and the different duration of
follow-up period among the included studies may be re-
sponsible for them. Moreover, the combination use of
BCG and MMC wasn’t significantly superior to MMC
alone. MMC may cause low efficacy of the combined
treatment, because it can repress the immune response
while preventing implantation of carcinoma. Basis re-
searches were awaited to conduct the issue.
IFN-α2b is thought to increase the response of Th1
cell caused by BCG instillation through multiple ap-
proaches such as inhibiting interleukin-10 and enhance
tumor necrosis factor-related apoptosis-inducing ligand
release, ultimately lead to the suppression and subse-
quent destruction of urothelial carcinoma [44,45]. But
we failed to observe a major efficacy after giving
intravesical IFN-α2b. However, IFN-α2b may be useful
for patients with BCG refractory cases, for whom the
BCG alone is insufficient to effectively awake the im-
mune response to carcinoma. The final results of a na-
tional multicenter study of BCG plus IFN-α2b for
treating superficial BCa confirmed the hypothesis [46].
The results showed a 59% and 45% recurrence-free rate
of patient naive to BCG and those having BCG failure at
a median follow-up of 24 months, respectively.
The overall results, except one, did not change re-
markably after subgroup and sensitivity analyses. Publi-
cation bias was only observed in one subgroup analysis,
which was proved by Egger’s test. Our analysis combined
the data from all studies that passed our predefined cri-
teria; therefore, we are confident of the validity of our
findings.
However, some inherent limitations of this meta-analysis
should also be taken into account when interpreting our
data. Firstly, most RCTs included in our analysis were of
low-quality, which was caused by obvious side-effects
which made it difficult to address double-blind. Another
limitation of this study is the publication bias observed in
subgroup analysis. This might impact the interpretation of
the results because unpublished data may overturn this
obtained result. So this result should be interpreted withcaution. One reason for the bias may be that only English
articles were searched, because other languages such as
German were out of our ability. This selection might favor
the positive studies that were more often published in
English while the negative ones tended to be more often
reported in native languages [47]. We attempted to
minimize the publication bias by making our literature
search as extensive as we could. Moreover, the clinical and
pathologic stages of patients that were important to the
oncologic prognosis were different in the included trials,
which might substantially confound the presented results.
Furthermore, slight difference of treatment schemes
existed in the same therapy schedules, so the studies with
standard schemes and enough follow-up time are
expected. Finally, different duration of follow-up period
among the included studies also affected the outcomes.
To lessen the effect of follow-up period on synthetic re-
sults, HRs (time variable was taken into account) were pri-
oritized in included studies.
Conclusions
Pooled result shows that BCG maintenance is associated
with better oncologic outcomes (e.g. RFS and PFS).
However, there is a higher incidence of adverse events.
Low-dose BCG can’t effectively prevent the recurrence
of tumor, though a slightly reduced incidence of LUTS is
observed. Compared with single BCG, combination with
epirubicin may significantly reduce recurrence but not
progression rate, and no more side-effect emerges. For
both RFS and PFS, combination BCG with MMC or
IFN-α2b is not superior to BCG and MMC alone. Given
that the low-quality of the included studies can’t be
overcomed, large-volume, well-designed, RCTs with ex-
tensive follow-up are needed to confirm and update our
findings.
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